PHARMACO KINETICS AND EFFECTS OF PROPRANOLOL IN TERMINAL UREMIC PATIENTS AND IN PATIENTS UNDERGOING REGULAR DIALYSIS TREATMENT
PHARMACO KINETICS AND EFFECTS OF PROPRANOLOL IN TERMINAL UREMIC PATIENTS AND IN PATIENTS UNDERGOING REGULAR DIALYSIS TREATMENT
复制标题
DOI:
10.2165/00003088-197601050-00004
复制
发表时间:
1976-01-01
影响因子:
4.5
通讯作者:
ET AL
中科院分区:
文献类型:
--
作者:
BIANCHETTI G;GRAZIANI G;ET AL
Propranolol blood and plasma levels were measured after a single oral dose of 40 mg in patients with chronic renal failure, in patients undergoing regular dialysis treatment and in healthy volunteers. Peak levels were observed in all cases within 1.5-3 h. Peak blood and plasma concentrations of propranolol in the chronic renal failure group were 2- to 3-fold higher (161 .+-. 41 ng/ml) than those observed in the dialysis patients (47 .+-. 9 ng/ml) and in the healthy volunteers (26 .+-. 1 ng/ml). The apparent plasma clearance was also significantly reduced in the patients with chronic renal failure. A reduced hepatic extraction is suggested in chronic renal failure patients. A significant increase in the fraction of the dose available to the systemic circulation was also found, together with a modification of apparent plasma half-life and volume of distribution in regular dialysis patients during the dialysis day as compared with the after-dialysis day. No extraction of propranolol by the dialyzer was noticed. Marked fluctuations in propranolol blood concentrations were also observed in patients on regular dialysis following continuous propranolol treatment. The suppressive effect of propranolol on plasma renin activity did not fully correlate with the hypotensive effect of the drug. Propranolol should be used with great caution and at low doses in chronic renal failure.